An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection

Brief description of study

The TARGET-HBV study engages an observational research design to conduct a comprehensive review of therapeutic outcomes for patients with chronic hepatitis B (HBV) who are currently taking tenofovir alafenamide (TAF). This study will engage research activities in phases, with a retrospective record evaluation of patients on TAF serving as the first phase. The study will address important clinical questions regarding the management of HBV with TAF and other oral therapies by collecting and analyzing data from patients at academic and community medical centers. TARGET-HBV creates a robust database of real-world data regarding the natural history, management, and health outcomes related to TAF.


Clinical Study Identifier: s18-01258
Principal Investigator: Viviana Figueroa Diaz
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.